EX-23.1 4 ex_533910.htm EXHIBIT 23.1 ex_533910.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the use of our report dated March 24, 2023, with respect to the consolidated financial statements of Diffusion Pharmaceuticals Inc., included herein, and to the reference to our firm under the heading “Experts” in the prospectus.

 

 

/s/ KPMG LLP

 

McLean, VA

June 20, 2023